| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014489A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014467A2 Cng2b: a putative human cyclic nucleotide-gated ion channel |
| 02/21/2002 | WO2002014448A2 Adhesive blends comprising hydrophilic and hydrophobic pressure sensitive adhesives |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014342A1 Steroid derived antibiotics |
| 02/21/2002 | WO2002014285A1 Substituted imidazoles as tafia inhibitors |
| 02/21/2002 | WO2002013882A1 Implants with a phosphazene-containing coating |
| 02/21/2002 | WO2002013866A2 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | WO2002013864A1 Medicinal compositions for preventing and treating cancer |
| 02/21/2002 | WO2002013835A1 Composition exhibiting synergistic antioxidant activity |
| 02/21/2002 | WO2002013833A2 SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013815A1 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 02/21/2002 | WO2002013812A1 Methods for treating inflammatory diseases |
| 02/21/2002 | WO2002013810A1 Water-soluble prodrugs of propofol for treatment of migraine |
| 02/21/2002 | WO2002013808A2 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | WO2002013803A2 Chelerythrine-based therapies for cancer |
| 02/21/2002 | WO2002013802A2 Method of treating estrogen receptor positive carcinoma |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013797A2 Therapeutic combination of a cetp inhibitor and atorvastatin |
| 02/21/2002 | WO2002013793A2 Method of making tablets and tablet compositions produced therefrom |
| 02/21/2002 | WO2002013791A2 Steroid hormones as transfer agents |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001082873A3 A medicinal aerosol formulation |
| 02/21/2002 | WO2001082863A3 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 02/21/2002 | WO2001080837A3 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076601A3 Pharmaceutical compositions comprising salmeterol and ipratropium |
| 02/21/2002 | WO2001074313A3 Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001072291A3 Treatment of movement disorders with metabotropic glutamate receptor antagonist |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068065A3 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 02/21/2002 | WO2001064246A3 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 02/21/2002 | WO2001062270A3 Method for treating hashimoto's thyroiditis |
| 02/21/2002 | WO2001058910A3 Lipid-based drug delivery systems |
| 02/21/2002 | WO2001058869B1 Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| 02/21/2002 | WO2001058484A3 Novel uses of mammalian ccr8 receptors and related reagents |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001047510A3 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 02/21/2002 | WO2001046698A3 Tethered ligands and methods of use |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001045717A3 Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001030323A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000078355A3 Biologically active materials |
| 02/21/2002 | WO2000069269A9 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
| 02/21/2002 | US20020022718 Genes identified as required for proliferation of E. coli |
| 02/21/2002 | US20020022658 Methods for selectively occluding blood supplies to neoplasias |
| 02/21/2002 | US20020022654 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 02/21/2002 | US20020022640 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022634 Method for treating alcohol intoxication and alcohol abuse |
| 02/21/2002 | US20020022629 A new class of quinolone antibiotic (e.g., moxifloxacin) is useful for treating otic, opthalmic or nasal infections attributed to a microbacterium species selected from microbacterium otitidis or microbacterium alconae |
| 02/21/2002 | US20020022625 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 02/21/2002 | US20020022603 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| 02/21/2002 | US20020022599 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/21/2002 | US20020022254 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | US20020022218 Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2 |
| 02/21/2002 | US20020022216 Preferential propagation of target cells; mix cells with propagation nutrients, monitor cell propagtion, recover preferential cells |
| 02/21/2002 | US20020022058 Oral consumable; mixture of therapy and nutrients |
| 02/21/2002 | US20020022034 Therapeutic DNA vaccination |
| 02/21/2002 | US20020022031 Immunotherapy for chronic myelocytic leukemia |
| 02/21/2002 | US20020022029 Human RRP sequences and methods of use |
| 02/21/2002 | US20020022028 Integrin antagonist; bone disorders |
| 02/21/2002 | US20020022027 Complexing to polypeptides; antiproliferation agent |
| 02/21/2002 | US20020022019 Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments |
| 02/21/2002 | US20020022003 Method and composition for the treatment of cancer by the enzymantic conversion of soluble radioactive toxic precipitates in the cancer |
| 02/21/2002 | EP1143935A3 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 02/21/2002 | DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands |
| 02/21/2002 | DE10039199A1 Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen Combination preparations of ERß a selective estrogen and a SERM or antiestrogen |
| 02/21/2002 | CA2431954A1 A retroviral immunotherapy |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419855A1 Stimulating neutrophil function to treat inflammatory bowel disease |
| 02/21/2002 | CA2419491A1 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | CA2419406A1 Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels |
| 02/21/2002 | CA2419405A1 Steroid hormones as transfer agents |
| 02/21/2002 | CA2419047A1 Water-soluble prodrugs of propofol for treatment of migraine |
| 02/21/2002 | CA2419033A1 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | CA2419020A1 Pyruvate:nadp+ oxidoreductase and uses thereof |
| 02/21/2002 | CA2418988A1 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| 02/21/2002 | CA2418982A1 Chelerythrine-based therapies for cancer |
| 02/21/2002 | CA2418725A1 Claudin polypeptides |
| 02/21/2002 | CA2418320A1 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 02/21/2002 | CA2418303A1 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | CA2415353A1 Use of antibodies against specific mhc-peptide complexes |
| 02/20/2002 | EP1180524A1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
| 02/20/2002 | EP1180371A1 Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin |
| 02/20/2002 | EP1180364A1 Steroid hormones as transfer agents |
| 02/20/2002 | EP1180239A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |